Sera Prognostics, Inc., (SERA): Price and Financial Metrics
SERA Price/Volume Stats
Current price | $9.46 | 52-week high | $10.44 |
Prev. close | $9.50 | 52-week low | $1.52 |
Day low | $9.06 | Volume | 396,700 |
Day high | $9.89 | Avg. volume | 238,718 |
50-day MA | $8.33 | Dividend yield | N/A |
200-day MA | $4.29 | Market Cap | 296.45M |
SERA Stock Price Chart Interactive Chart >
SERA Stock Summary
- SERA's went public 2.47 years ago, making it older than just 5.71% of listed US stocks we're tracking.
- For SERA, its debt to operating expenses ratio is greater than that reported by just 8.57% of US equities we're observing.
- SERA's price/sales ratio is 522.28; that's higher than the P/S ratio of 99.05% of US stocks.
- If you're looking for stocks that are quantitatively similar to SERA PROGNOSTICS INC, a group of peers worth examining would be CLPT, TARS, LAW, AXTI, and NSPR.
- To check out SERA PROGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001534969.
SERA Valuation Summary
- SERA's price/sales ratio is 567.9; this is 25713.64% higher than that of the median Healthcare stock.
- SERA's EV/EBIT ratio has moved up 12.2 over the prior 30 months.
Below are key valuation metrics over time for SERA.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SERA | 2023-12-29 | 567.9 | 2.5 | -4.9 | -4.7 |
SERA | 2023-12-28 | 634.2 | 2.8 | -5.5 | -5.3 |
SERA | 2023-12-27 | 601.2 | 2.6 | -5.2 | -5.0 |
SERA | 2023-12-26 | 603.9 | 2.6 | -5.2 | -5.0 |
SERA | 2023-12-22 | 625.8 | 2.7 | -5.4 | -5.2 |
SERA | 2023-12-21 | 631.5 | 2.8 | -5.5 | -5.3 |
SERA Price Target
For more insight on analysts targets of SERA, see our SERA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $18.00 | Average Broker Recommendation | 1.17 (Strong Buy) |
Sera Prognostics, Inc., (SERA) Company Bio
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest SERA News From Around the Web
Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.
Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to BuyDoes Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out. |
While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail investors stood to gain the mostKey Insights Significant control over Sera Prognostics by retail investors implies that the general public has more... |
Stocks Edge Higher On Hopes Of Soft Economic LandingEasing labor costs, rising productivity, and a cooling labor market are supporting Wall Street this afternoon. |
Why Is Sera Prognostics (SERA) Stock Up 260% Today?With an oversight board recommending Sera Prognostics halt its clinical study for efficacy, SERA stock soared on the positive implications. |
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESSSera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stoppi |
SERA Price Returns
1-mo | 6.29% |
3-mo | 58.19% |
6-mo | 408.60% |
1-year | 148.95% |
3-year | N/A |
5-year | N/A |
YTD | 58.19% |
2023 | 374.60% |
2022 | -81.66% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...